G A Abel

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Delays in referral and diagnosis for chronic hematologic malignancies: a literature review
    Gregory A Abel
    Department of Medical Oncology, Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leuk Lymphoma 49:1352-9. 2008
  2. ncbi Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions
    Gregory A Abel
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer 119:1065-72. 2013
  3. ncbi Referrals for suspected hematologic malignancy: a survey of primary care physicians
    Gregory A Abel
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Am J Hematol 87:634-6. 2012
  4. ncbi High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database
    Gregory A Abel
    Brigham and Women s Hospital, Boston, MA, USA
    Leuk Lymphoma 53:1113-6. 2012
  5. ncbi Classification of the myelodysplastic syndrome in a national registry of recently diagnosed patients
    Gregory A Abel
    Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Leuk Res 34:939-41. 2010
  6. ncbi Outcomes for lymphoid malignancies in the Nurses' Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) Program
    Gregory A Abel
    Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Hematol Oncol 28:133-6. 2010
  7. ncbi Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment
    Gregory A Abel
    Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Smith 271, Boston, MA 02115, USA
    J Clin Oncol 27:4182-7. 2009
  8. ncbi Direct-to-consumer advertising for bleeding disorders: a content analysis and expert evaluation of advertising claims
    G A Abel
    Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Thromb Haemost 6:1680-4. 2008
  9. ncbi Chemotherapy as language: sound symbolism in cancer medication names
    Gregory A Abel
    Department of Medical Oncology, Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney Street, Smith 271, Boston, MA 02115, USA
    Soc Sci Med 66:1863-9. 2008
  10. ncbi Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network
    Ann S LaCasce
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:5107-12. 2008

Detail Information

Publications12

  1. ncbi Delays in referral and diagnosis for chronic hematologic malignancies: a literature review
    Gregory A Abel
    Department of Medical Oncology, Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leuk Lymphoma 49:1352-9. 2008
    ..Unfortunately, the outcomes associated with such delays are largely unreported, possibly because delay is complex to define and difficult to measure...
  2. ncbi Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions
    Gregory A Abel
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer 119:1065-72. 2013
    ....
  3. ncbi Referrals for suspected hematologic malignancy: a survey of primary care physicians
    Gregory A Abel
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Am J Hematol 87:634-6. 2012
    ..We conclude that anemia plus signs and symptoms suggestive of myelodysplasia or leukemia (compared with those suggestive of lymphoma) are more likely to prompt hematology referral. In addition, given their rarity,the numbe..
  4. ncbi High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database
    Gregory A Abel
    Brigham and Women s Hospital, Boston, MA, USA
    Leuk Lymphoma 53:1113-6. 2012
    ..Our results suggest that despite limited data regarding its effect on outcomes, surveillance imaging is prevalent in DLBCL, and a majority of patients receive PET scans at some point during follow-up...
  5. ncbi Classification of the myelodysplastic syndrome in a national registry of recently diagnosed patients
    Gregory A Abel
    Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Leuk Res 34:939-41. 2010
    ..It is not known to what extent the WHO classification scheme for MDS has been adopted in clinical practice...
  6. ncbi Outcomes for lymphoid malignancies in the Nurses' Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) Program
    Gregory A Abel
    Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Hematol Oncol 28:133-6. 2010
    ..26 [1.07, 1.48]). Our analysis suggests that, at least among white women, SEER is a reliable data source with respect to lymphoid malignancies...
  7. ncbi Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment
    Gregory A Abel
    Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Smith 271, Boston, MA 02115, USA
    J Clin Oncol 27:4182-7. 2009
    ..Although cancer-related direct-to-consumer advertising (CR-DTCA) is prevalent, little is known about cancer patients' experiences with this controversial medium of medical communication...
  8. ncbi Direct-to-consumer advertising for bleeding disorders: a content analysis and expert evaluation of advertising claims
    G A Abel
    Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Thromb Haemost 6:1680-4. 2008
    ..DTCA for medications to treat rare diseases such as bleeding disorders is unlikely to be given high priority for FDA review...
  9. ncbi Chemotherapy as language: sound symbolism in cancer medication names
    Gregory A Abel
    Department of Medical Oncology, Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney Street, Smith 271, Boston, MA 02115, USA
    Soc Sci Med 66:1863-9. 2008
    ..This finding raises important questions about the possible role of the names of medications in the experiences of cancer patients and providers...
  10. ncbi Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network
    Ann S LaCasce
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:5107-12. 2008
    ..We sought to estimate the impact of expert review in the modern era by comparing final pathologic diagnoses at five comprehensive cancer centers with diagnoses assigned at referring centers...
  11. ncbi Direct-to-consumer advertising in oncology
    Gregory A Abel
    Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114-2617, USA
    Oncologist 11:217-26. 2006
    ..Although sparse, the medical literature on this increasingly prevalent type of medical communication is also reviewed...
  12. ncbi Direct-to-consumer advertising in oncology: a content analysis of print media
    Gregory A Abel
    Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:1267-71. 2007
    ..Content analysis of cancer-related direct-to-consumer advertising (DTCA), with a focus on how benefit and risk/adverse effect information is presented, is essential to understanding its potential impact on oncology outcomes...